The propionyl-L-carnitine hypothesis: An alternative approach to treating heart failure

Journal of Cardiac Failure

Volumn 3, Issue 3, 1997, Pages 217-224

  Ferrari, Roberto ^a,b   De Giuli, Federica ^a  

^a c/o Spedali Civili ^*

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOTONIC AGENT; CARNITINE; DRUG DERIVATIVE; PROPIONYLCARNITINE;

ANIMAL; BIOLOGICAL MODEL; CHRONIC DISEASE; CONGESTIVE HEART FAILURE; DISEASE MODEL; DRUG EFFECT; HEART; HUMAN; MUSCLE; RABBIT; RAT; REVIEW;

ANIMALS; CARDIOTONIC AGENTS; CARNITINE; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; HEART; HEART FAILURE, CONGESTIVE; HUMANS; MODELS, BIOLOGICAL; MUSCLES; RABBITS; RATS;

EID: 0031225955     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1071-9164(97)90018-x     Document Type: Review

References (68)

1. Anonymous: Drug development for life-threatening illnesses is taking under five years on average. FDA says: early NDAs before study completion are key. FDC Rep 1989;51:7-9
2. Corr PR, Creer MH, Yimada KA, Saffitz JE, Sobel BE: Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation. J Clin Invest 1989;83:927-36
3. Cherchi A, Lai C, Angelino F, Trucco G, Caponnetto S, Mereto PE, Rosolen G, Manzoli U, Schiavoni G, Reale A, Romeo F, Rizzon P, Sorgente L, Strano A, Novo S, Immordino E: Effects of L-carnitine on exercise tolerance in chronic stable angina: a multicenter, double-blind, randomized, placebo controlled crossover study. Int J Clin Pharmacol Ther Toxicol 1985;23:569-72
4. Carnitine deficiency. (Editorial) Lancet 1990;335:631-2
5. Brevetti G, Chiariello M, Ferulano GI, Policicchio H, Nevola E, Rossini A, Attisano T, Ambrosio G, Suuprano N, Angelini C; Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation 1988;77:767-73
6. Iliceto S, Scrutinio D, Bruzzi P, D'Ambrosio G, Boni L, Di Biase M, Biasco G, Hugenoltz PG, Rizzon P: Effect of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) trial. J Am Coll Cardiol 1995;26:380-7
7. De Jong JW, Ferrari R: Effect of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a summary. In De Jong JW, Ferrari R: The carnitine system: a new therapeutical approach to cerebrovascular diseases. Kluwer Academic Publishers, Boston, 1995, pp. 383-8
8. Vockley J: The changing face of disorders of fatty acid oxidation. Mayo Clin Proc 1994;69:249-57
9. Tripp ME, Katcher ML, Peters HA: Systemic carnitine deficiency presenting as familiar endocardial fibroelastosis: a treatable cardiomyopathy. N Engl J Med 1980;305: 385-90
10. Waber LJ, Valle D, Neill C, Di Mauro S, Shug A: Carnitine deficiency presenting as familial cardiomyopathy: a treatable defect in carnitine transport. J Pediatr 1982; 101: 700-5
11. Suzuki Y, Masumuro Y, Kobayashi A, Yamazaki L, Harada Y, Osawa M: Myocardial carnitine deficiency in congestive heart failure. Lancet 1982;i:116
12. Regitz V, Shug AL, Fleck E: Defective myocardial metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart disease. Am J Cardiol 1990;65:755-60
13. Regitz V, Shug AL, Schuler S, Yankah AC, Hetze R: Herzinsufficienz bei dilatativer kardiomyopathie und koronarer herzerkrankung- beitrag biochemischer parameter zur beurteilung der prognose. Dtsch Med Wochenschr 1988;113:781-6
14. Regitz V, Muller M, Schuler S, Yankah CA, Heyzer R, Shug AL, Fleck E: Carnitinstoffwechsel-veranduregen in endetadium der dilatativen kardiomyopathie und der ischamischen herzmuskeler-krankung. Z Kardiol 1987;76: 1-8
15. Figueiredo Ramos ACM, Elian PRP, Barrucand L, Da Silva JAF: The protective effect of carnitine in human diphtheric myocarditis. Pediatr Res 1984;18:815-9
16. De Leonardis V, Neri B, Baculli S, Cinelli P: Reduction cardiac toxicity of anthracyclines by L-carnitine preliminary overview of clinical data. Int J Clin Pharmacol Res 1985;5:137-42
17. Cevese A, Schena F, Cerutti G: Short-term hemodynamic effects of intravenous propionyl-L-carnitine in anesthetized dogs. Cardiologia 1989;34:95-101
18. Cevese A, Schena F, Cerutti G: Short-term hemodynamic effects of intravenous propionyl-L-carnitine in anesthetized dogs. Cardiovasc Drugs Ther 1991;5(suppl. 1):45-56
19. Chiddo A, Musci S, Bortone A, Troito G, Locuratolo N, Gaglione A, Rizzon P: Effetti emodinamici e sul circolo coronarico della propionyl-L-carnitina. Cardiologia 1989; 34(suppl. 1):111-7
20. Chiddo A, Gaglione A, Musci S, Troito G, Grimaldi N, Locuratolo N, Rizzon P: Hemodynamic study of intravenous propionylL-carnitine in patients with ischemic heart disease and normal left ventricular function. Cardiovasc Drugs Ther 1991;5(supp. 1):107-12
21. Tassani V, Cattapan L, Magnanimi L, Peschechera A: Anaplerotic effect of propionyl-L-carnitine in rat heart mitochondria. Biochem Biophys Res Commun 1994; 199: 949-53
22. Zweier JL, Jacobus E: Substrate-induced alteration of high energy phosphate metabolism and contractile function in the perfused heart. J Biol Chem 1987;262:8015-21
23. Ferrari R, Di Lisa F, De Jong JW, Ceconi C, Pasini E, Barbato R, Menabo R, Bardiro M, Cerrai B, Mucelli A: Prolonged propionyl-L-carnitine pretreatment of rabbit: biochemical, hemodynamic and electrophysiological effects on myocardium. J Mol Cell Cardiol 1992;24:219-32
24. Barbieri M, Carbonin PU, Cerbal E, Giatbassi GJ, Lo Guidi CE, Masini I, Mucelli A, Pahor M: Lack of correlation between the antiarrhythmic effect of L-propionylcarnitine on reoxygenation-induced arrhythmias and its electrophysiological properties. Br J Pharmacol 1991; 102:73-8
25. Micheletti R, Donato di Paola E, Schiavone A, Rossi R, Bianchi G: Effect of propionyl-L-carnitine and enalapril on cardiac function of pressure-overloaded rats during acute increase in load. Eur J Pharmacol 1995;286:147-54
26. Cevese A, Schena F, Cerutti G: Short-time hemodynamic effects of intravenous propionyl-L-carnitine in anesthetized dogs. Cardiovasc Drugs Ther 1991;5:45-56
27. Schonekess BG, Allard MF, Lopaschuk GD: Propionyl-L-carnitine improvement of hypertrophied heart function is accompanied by an increase in carbohydrate oxidation. Circ Res 1995;77:726-34
28. Li P, Park C, Micheletti R, Cheng W, Sonnenblick EH, Anversa P, Bianchi G: Myocyte performance during the evolution of myocardial infarction in rats: effects of propionyl-L-carnitine. Am J Physiol 1995;268:H1702-13
29. Ferrari R, Pasini E, Condorelli E, Blaso A, Liscani R, Mazzo A, Visioli O: Effect of propionyl-L-carnitine on mechanical function of isolated rabbit heart. Cardiovasc Drugs Ther 1991;5:17-24
30. Pasini E, Comini L, Ferrari R, de Giuli F, Menotti A, Dhalla NS: Effect of propionyl-L-carnitine on experimentally induced cardiomyopathy in rats. Am J Cardiovasc Pathol 1992;4:216-22
31. Schonekess BG, Allard MF, Lopaschuk GD: Propionyl-L-carnitine improvement of hypertrophied heart function is associated with an increase in cardiac efficiency. Eur J Pharmacol 1995;286:155-66
32. Micheletti R, Giacalone G, Canepari M, Salardi S, Bianchi G, Reggiani C: Propionyl-L-carnitine prevents myocardial mechanical alterations due to pressure overload in rats. Am J Physiol 1994;266:H2190-7
33. Yang XP, Samaja M, English B, Benatti P, Tarantola M, Cardace G, Motterlini R, Micheletti R, Bianchi G: Haemodynamic and metabolic activities of propionyl-L-carnitine in rats with pressure-overload cardiac hypertrophy. J Cardiovasc Pharmacol 1992;20:88-98
34. Torielli L, Conti F, Cinato E, Ceppi E, Anversa P, Bianchi G, Ferrari P: Alterations in energy metabolism of hypertrophied rat cardiomyocytes: influence of propionyl-L-carnitine. J Cardiovasc Pharmacol 1995;26:372-80
35. Broderick TL, Quinney HA, Barker CC, Lopaschuk GD: Beneficial effect of carnitine on mechanical recovery of rat hearts reperfused after a transient period of global ischemia is accompanied by a stimulation of glucose oxidation. Circulation 1993;87:972-81
36. Leipala JA, Bhatnagar R, Pineda E, Najibi S, Massoumi K, Packer L: Protection of the reperfused heart by L-propionylcarnitine. J Appl Physiol 1991;71:1518-22
37. Paulson DJ, Traxler J, Schmidt M, Noonan J, Shug AL: Protection of the ischaemic myocardium by L-propionyl-carnitine: effects on the recovery of cardiac output after ischaemia and reperfusion, carnitine transport, and fatty acid oxidation. Cardiovasc Res 1986;20:536-41
38. Micheletti R, Schiavone A, English E, Benatti P, Caposso JM, Anversa P, Bianche G: Propionyl-L-carnitine limit chronic ventricular dilatation after myocardial infarction in rats. Am J Physiol 1993;264:H1111-7
39. Li P, Micheletti R, Park C, Li BS, Anversa P, Bianchi G: Propionyl-L-carnitine ameliorates myocyte performance after infarction. Can J Cardiol 1994;10:85 (abstr)
40. Pasini E, Comini L, Ferrari R, De Giuli F, Menotti A, Dhalla NS: Effect of propionyl-L-carnitine on experimental induced cardiomyopathy in rats. Am J Cardiovasc Pathol 1992;4:216-22
41. Dhalla NS, Kolar F, Shah KR, Ferrari R: Effects of some Lcarnitine derivatives on heart membrane ATPases. Cardiovasc Drug Ther 1991;5:25-30
42. Lopaschuck GD, Tahiliani AG, Vadlamudi RVSU, Katz S, McNell JH: Cardiac sarcoplasmic reticulum in insuline-or-carnitine treated diabetic rats. Am J Physiol 1983; 245:H969-76
43. Siliprandi N, Di Lisa F, Rossi CR, Toninello A: Overview of lipid metabolism. In Ferrari R, Katz AM, Shug A, Visioli O: Myocardial ischemia and lipid metabolism. Plenum, New York, 1984, pp. 1-13
44. Di Lisa F, Menabo' R, Barbato R, Siliprandi N: Contrasting effects of propionate and propionyl-L-carnitine on energy-linked processes in ischemic heart. Am J Physiol 1994;267:H455-61
45. Broderick TL, Quinney HA, Lopaschuk GD: Carnitine stimulation of glucose oxidation in the fatty acid perfused isolated working heart. J Biol Chem 1992;267: 3758-763
46. Lysiak W, Lilly K, Di Lisa F, Roth PP, Bieber LL: Quantification of the effect of L-carnitine on the levels of acid-soluble short-chain acyl CoA and CoA in rat heart and liver mitochondria. J Biol Chem 1988;263:1511-6
47. Allard MS, Schonekessbo H: The contributors of oxidative metabolism and glycolysis to ATP production in hypertro-phied heart. Am J Physiol 1994;267:H742-50
48. Lipkin DP, Canepa-Anson R, Stephens MR, Poole-Wilson PA: Factors determining symptoms in heart failure: comparison of fast and slow exercise tests. Br Heart J 1986; 55:439-45
49. Poole-Wilson PA: Relation of pathophysiologic mechanisms to outcome in heart failure. J Am Coll Cardiol 1993; 22:22A-9A
50. Wilson JR, Martin JL, Schwartz D, Ferraro N: Exercise intolerance in patients with chronic heart failure: role of impaired skeletal muscle nutritive flow. Circulation 1984; 69:1079-87
51. Lipkin DP, Poole-Wilson PA: Symptoms limiting exercise in chronic heart failure. Br Med J 1986;292:1030-1
52. Wilson JR, Mancini DM: Factors contributing to exercise limitation of heart failure. J Am Coll Cardiol 1993;22: 93A-8A
53. Ferrari R, Pasini E, de Giuli F, Opasich C, Cobelli F, Tavazzi L: Limp uptake of substrate in patients with congestive heart failure (CHF). Can J Cardiol 1994;10:41A (abstr)
54. Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris P: Edema of cardiac origin, studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 1989;80:299-305
55. Wilson JR, Ferraro N, Wiener DH: Effect of the sympathetic nervous system on limb circulation and metabolism during exercise in heart failure. Circulation 1985;72:72-81
56. Gibbons GH, Dzau VJ: The emerging concept of vascular remodeling. N Engl J Med 1994;330:1431-8
57. Weiner DH, Fink LI, Maris J, Jones RA, Chance B, Wilson JR: Abnormal skeletal muscle bioenergetics during exercise in patients with heart failure: role of reduced muscle blood flow. Circulation 1986;73:1127-36
58. Regensteiner JG, Wolfel EE, Brass E, Carry MR, Ringel SP, Hargarten ME, Stamm ER, Hiatt WR: Chronic changes in skeletal muscle histology and function in peripheral arterial disease. Circulation 1993;87:413-21
59. Sullivan MJ, Higginbothan MB, Cobb FR: Exercise training in patients with severe left ventricular dysfunction: hemodynamic and metabolic effects. Circulation 1988; 78:506-15
60. Coats A, Adamopoulos S, Radaelli A, McCance A, Meyer TE, Bernardi L, Solda PL, Davey P, Ormerod O, Fortac C: Controlled trial of physical training in chronic heart failure. Circulation 1992;85:2119-31
61. Wilson JR, Fink L, Maris J: Evaluation of skeletal muscle energy metabolism in patients with heart failure using gated phosphoras-31 nuclear magnetic resonance. Circulation 1985;71:57-62
62. Opasich C, Pasini E, Aquilani R, Cobelli F, Solfrini R, Ferrari R, Tavazzi L: Skeletal muscle metabolism abnormalities and daily life activity in chronic heart failure. Eur Heart J, in press
63. Brevetti G, Chiariello M, Ferulano G, Policicchio A, Nevola E, Rossini A, Attisano T, Ambrosio G, Siljrandi N, Angelini C: Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation 1988;77: 767-83
64. Anand I, Chandrashekhar Y, de Giuli F, Pasini E, Mazzoletti A, Confortini R, Ferrari R: Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther, in press
65. Caponetto S, Canale C, Masperone MA, Terrachini V, Valentini G, Brunelli C: Efficacy of L-propionyl-carnitine treatment in patients with left ventricular dysfunction. Eur Heart J, in press
66. Mancini M, Rengo S, Lingetti M, Sorrentino GP, Nolfe G: Control study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. Arzneimittelforschung 1992;42:1101-4
67. Bachetti T, Corti A, Cassani G, Confortini R, Mazzoletti A, Ferrari R: Cytokines in end stage congestive heart failure: effect of propionyl-L-carnitine. Can J Cardiol 1994;10:66 (abstr)
68. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, Cassani G, Visioli O: Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995;92:1478-86